Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients

Circulation: Cardiovascular Genetics

Volumn 3, Issue 2, 2010, Pages 162-168

  Hyde, Craig L ^a   MacInnes, Alan ^a   Sanders, Frances A ^c   Thompson, John F ^b   Mazzarella, Richard A ^a   Faergeman, Ole ^d   Van Wijk, Diederik F ^e   Wood, Linda ^a   Lira, Maruja ^a   Paciga, Sara A ^a  

^a PFIZER INC   (United States)

^b Helicos BioSciences   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

CCR5 32; Genetics; Genotype; Lipids; Single nucleotide polymorphism

Indexed keywords

ATORVASTATIN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCRL2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHROMOSOME 3; CONTROLLED STUDY; GENE CLUSTER; GENE DELETION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; GENE DELETION; GENE FREQUENCY; GENOTYPE; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRROLES; RECEPTORS, CCR; RECEPTORS, CCR5; RETROSPECTIVE STUDIES; RISK FACTORS; SIMVASTATIN; TRIGLYCERIDES;

EID: 77953668255     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.109.897793     Document Type: Article

References (28)

1. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508-519.
2. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res. 2004;95:858-866.
3. Schober A, Zernecke A. Chemokines in vascular remodeling. Thromb Haemost. 2007;97:730-737.
4. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal. 2004;16:1201-1210.
5. Lucas AD, Greaves DR. Atherosclerosis: role of chemokines and macrophages. Expert Rev Mol Med. 2001;3:1-18.
6. Potteaux S, Combadiére C, Esposito B, Lecureuil C, Ait-Oufella H, Merval R, Ardouin P, Tedgui A, Mallat Z. Role of bone marrow-derived CC-chemokine receptor 5 in the development of atherosclerosis of lowdensity lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol. 2006;26:1858-1863.
7. Quinones MP, Martinez HG, Jimenez F, Estrada CA, Dudley M, Willmon O, Kulkarni H, Reddick RL, Fernandes G, Kuziel WA, Ahuja SK, Ahuja SS. CC chemokine receptor 5 influences late-stage atherosclerosis. Atherosclerosis. 2007;195:e92-e103.
8. Braunersreuther V, Zernecke A, Arnaud C, Liehn EA, Steffens S, Shagdarsuren E, Bidzhekov K, Burger F, Pelli G, Luckow B, Mach F, Weber C. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2007;27:373-379.
9. van Wanrooij EJ, Happé H, Hauer AD, de Vos P, Imanishi T, Fujiwara H, van Berkel TJ, Kuiper J. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25:2642-2647.
10. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AE, Mach F. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res. 2004;94:253-261.
11. Martinson J, Chapman N, Rees D, Liu, Y-T, Clegg J. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet. 1997;16:100-103.
12. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognauz J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722-725.
13. Benkirane M, Jin DY, Chun RF, Koup RA, Jeang KT. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by CCR5delta32. J Biol Chem. 1997;272:30603-30606.
14. Pacheco SE, Gibbs RA, Ansari-Lari A, Rogers P. Intranasal immunization with HIV reverse transcriptase: effect of dose in the induction of helper T cell type 1 and 2 immunity. AIDS Res Hum Retroviruses. 2000;16:2009-2017.
15. González P, Alvarez R, Batalla A, Requero JR, Alvarez V, Astudillo A, Cubero GI, Cortina A, Coto E. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun. 2001;2:191-195.
16. Szalai C, Duba J, Prohászka Z, Kalina A, Szabó T, Nagy B, Horváth L, Császár A. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1-2518G/G genotype in CAD patients. Atherosclerosis. 2001;158:233-239.
17. Afzal AR, Kiechl S, Daryani YP, Weerasinghe A, Zhang Y, Reindl M, Mayr A, Weger S, Xu Q, Willeit J. Common CCR5-del32 frameshift mutation associated with serum levels of inflammatory markers and cardiovascular disease risk in the Bruneck population. Stroke. 2008;39:1972-1978.
18. Balistreri CR, Candore G, Caruso M, Incalcaterra E, Franceschi C, Caruso C. Role of polymorphisms of CC-chemokine receptor-5 gene in acute myocardial infarction and biological implications for longevity. Haematologica. 2008;93:637-638.
19. Simeoni E, Winkelmann BR, Hoffmann MM, Fleury S, Ruiz J, Kappenberger L, März W, Vassalli G. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J. 2004;25:1438-1446.
20. Petrkova J, Cermakova Z, Lukl J, Petrek M. CC chemokine receptor (CCR5) deletion polymorphism does not protect Czech males against early myocardial infarction. J Intern Med. 2005;257:564-566.
21. Apostolakis S, Baritaki S, Kochiadakis GE, Igoumenidis NE, Panutsopulos D, Spandidos DA. Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease. Thromb Res. 2007;119:63-71.
22. Sharda S, Gilmour A, Harris V, Singh VP, Sinha N, Tewari S, Ramesh V, Agrawal S, Mastana S. Chemokine receptor 5 (CCR5) deletion polymorphism in North Indian patients with coronary artery disease. Int J Cardiol. 2008;124:254-258.
23. Ghilardi G, Biondi ML, Turri O, Pateri F, d'Eril GM, Scorza R. Genetic control of chemokines in severe human internal carotid artery stenosis. Cytokine. 2008;41:24-28.
24. Pai JK, Kraft P, Cannuscio CC, Manson JE, Rexrode KM, Albert CM, Hunter D, Rimm EB. Polymorphisms in the CC-chemokine receptor-2 (CCR2) and -5 (CCR5) genes and risk of coronary heart disease among US women. Atherosclerosis. 2006;186:132-139.
25. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shephard J, Wender NK; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
26. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Palmer G; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. Am J Cardiol. 2004;94:720-724.
27. Nabatov AA, Pollakis G, Linnemann T, Paxton WA, de Baar MP. Statins disrupt CCR5 and RANTES expression levels in CD4 T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1. PLoS One. 2007;2:e470.
28. Fujino M, Miura S, Matsuo Y, Tanigawa H, Kawamura A, Saku K. Pitavastatin-induced downregulation of CCR2 and CCR5 in monocytes is associated with the arrest of cell-cycle in S phase. Atherosclerosis. 2006;187:301-308.